
PharmaCyte Biotech, Inc. — Investor Relations & Filings
PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company focused on developing and commercializing cellular therapies for cancer and diabetes. The company's core platform is its proprietary Cell-in-a-Box® technology, a cellulose-based live-cell encapsulation system. This technology involves encapsulating genetically engineered living cells that can produce and deliver therapeutic agents in a targeted manner when implanted in the body. The primary application under development is for the treatment of locally advanced, inoperable pancreatic cancer and other solid tumors, where the encapsulated cells are designed to convert an inactive chemotherapy drug into its active form at the tumor site.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| DEFINITIVE PROXY STATEMENT | 2025-03-10 | English | |
| FORM 8-K | 2025-02-26 | English | |
| Major Shareholding Notification 2025 | 2025-02-13 | English | |
| Major Shareholding Notification 2025 | 2025-01-15 | English | |
| FORM 10-Q FOR OCTOBER 2024 | 2024-12-13 | English | |
| REGISTRATION STATEMENT | 2024-12-04 | English |
Browse filings by year
26 years- 2026 3 filings
- 2025 31 filings
- 2024 20 filings
- 2023 44 filings
- 2022 50 filings
- 2021 41 filings
- 2020 10 filings
- 2019 9 filings
- 2018 7 filings
- 2017 14 filings
- 2016 17 filings
- 2015 12 filings
- 2014 35 filings
- 2013 13 filings
- 2012 16 filings
- 2011 34 filings
- 2010 16 filings
- 2009 18 filings
- 2008 4 filings
- 2007 8 filings
- 2006 8 filings
- 2005 14 filings
- 2004 19 filings
- 2003 5 filings
- 2002 3 filings
- 2001 1 filing
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
4 filings
| |||||
| 11459988 | DEFINITIVE PROXY STATEMENT | 2025-03-10 | English | ||
| 11459985 | FORM 8-K | 2025-02-26 | English | ||
| 11459986 | Major Shareholding Notification 2025 | 2025-02-13 | English | ||
| 11459987 | Major Shareholding Notification 2025 | 2025-01-15 | English | ||
|
2024
11 filings
| |||||
| 11459997 | FORM 10-Q FOR OCTOBER 2024 | 2024-12-13 | English | ||
| 11459990 | REGISTRATION STATEMENT | 2024-12-04 | English | ||
| 11459989 | AMENDMENT NO. 4 TO SCHEDULE 13G | 2024-11-13 | English | ||
| 11459991 | FORM 10-Q FOR JULY 2024 | 2024-09-17 | English | ||
| 11459992 | EXTENSION | 2024-09-16 | English | ||
| 11459993 | FORM 10-K FOR APRIL 2024 | 2024-08-13 | English | ||
| 11459995 | FORM 12B-25 | 2024-07-29 | English | ||
| 11459994 | Director's Dealing 2024 | 2024-07-17 | English | ||
| 11459996 | Director's Dealing 2024 | 2024-07-17 | English | ||
| 11459999 | Director's Dealing 2024 | 2024-07-17 | English | ||
| 11459998 | Director's Dealing 2024 | 2024-07-17 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
PharmaCyte Biotech, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35351/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35351 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35351 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35351 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35351}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for PharmaCyte Biotech, Inc. (id: 35351)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.